Name: | Description: | Size: | Format: | |
---|---|---|---|---|
1.48 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Microparticles (MPs) of konjac glucomannan (KGM) are proposed in this thesis as an
alternative therapeutic approach for antitubercular drug delivery to the lung, in the
ambit of tuberculosis (TB) therapy. KGM is composed of mannose groups that might
comprise an entry mechanism in macrophages infected with Mycobacterium
tuberculosis, mimicking one of the input paths of this infectious agent causer of TB. For
this purpose, KGM MPs need to have certain properties, in particular an aerodynamic
diameter between 1 and 3 μm that enables reaching the alveolar zone. These properties
might be attained by a production using spray-drying technology. The objective of this
work was to produce MPs of KGM through this process and associate two first-line
antitubercular drugs, isoniazid (INH) and rifabutin (RFB). Furthermore, the effect of
incorporating mannitol or leucine in the microparticle formulations was evaluated,
regarding MPs aerodynamic characteristics, drug association and release, and
biocompatibility profile.
After an initial optimization that required a hydrolysis of the original KGM polymer to
enable spray-drying, several formulations of MPs were produced and characterised. The
use of mannitol or leucine has demonstrated to improve the flow properties of some
formulations, as did the association of RFB. However, the incorporation of excipients
brought some disadvantages, especially regarding the in vitro release rate of the drug,
which became faster. Additionally, the incorporation of mannitol was found to affect the
association of INH, which became lower, suggesting a competing effect between INH
and mannitol. Cytotoxicity assays in alveolar epithelial cells revealed that RFB-loaded
KGM MPs may have a considerably toxic effect when used at a concentration of 1
mg/mL, in particular if MPs are also comprised of leucine.
The obtained results indicate that KGM MPs are suitable inhalable delivery systems for
antitubercular drugs. Considering that a combination of drugs is advised by WHO in TB
treatment, no benefit was found to occur from the incorporation of either leucine or
mannitol in the formulation of KGM MPs.
Description
Dissertação de mestrado, Ciências Biomédicas, Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, 2015
Keywords
Ciências biomédicas Tuberculose pulmonar Tratamento Resistência Transportadores Micropartículas Polímeros